Opinion|Videos|November 28, 2025
Nonstatin Therapy Decisions
Panelists discuss how nonstatin agents are chosen and when combination therapy should be introduced for high-risk patients.
Advertisement
Episodes in this series
Panelists discuss how clinicians decide when to introduce nonstatin low-density lipoprotein (LDL)–lowering agents such as ezetimibe or PCSK9 inhibitors. The choice depends on residual LDL levels, patient risk category, and prior therapy response.
They emphasize early combination therapy for high-risk patients, noting that waiting for repeated therapy failures delays optimal outcomes.
Panelists stress that structured treatment algorithms and patient follow-up can ensure timely intensification and reduce long-term cardiovascular risk.
Advertisement
Related to this article
Merck has begun the phase 3 ENHANCE-3 trial testing whether ensifentrine added to standard of care prevents COPD exacerbations in high-risk adults.
Non-CF bronchiectasis prevalence rose across commercial, Medicare, and Medicaid plans from 2016 to 2024, while incidence stayed relatively stable.
Shorter telomere length was linked to a usual interstitial pneumonia pattern (UIP) on CT in patients with ILD, per research presented at CHEST 2026.
Low awareness that fatty liver can silently progress and that MASH fibrosis is treatable drives missed follow-up testing, says Rohit Loomba, MD.
The FDA approved asundexian (Sunharbo) with antiplatelet therapy to reduce recurrent stroke risk after noncardioembolic stroke or high-risk TIA.
The FDA granted accelerated approval to amivantamab and hyaluronidase for previously treated recurrent or metastatic head and neck cancer.
Advertisement
Advertisement
Trending on AJMC
1
Payers, Eosinophil Thresholds Shape Who Gets a COPD Biologic
2
AHIP's Jeanette Thornton on Prior Authorization Reform, Midterms
3
US Measles Outbreaks Cost Nearly $83 Million in 2026
4
The Liver Meeting 2026 Highlights Hepatitis Delta, PBC Targets, MASH Costs
5